Presentation of the result of Medivir’s voluntary redemption programme

Stockholm, Sweden — Medivir AB (OMX: MVIR) announces the result of Medivir’s voluntary redemption programme. The redemption programme comprised a total of 4,465,717 shares in Medivir. Upon completion of the application period, at total of 4,293,990 shares have been registered for redemption, whereof 53,642 series A shares and 4,240,348 series B shares, corresponding to an acceptance level of 96.2 per cent. In total, cash proceeds of approximately SEK 601.2 million will be distributed to the shareholders, corresponding to SEK 140 per redeemed share, to be paid around 17 March 2015.

Following completion of the redemption programme, the total number of outstanding shares in Medivir will amount to 26,966,037 shares, whereof 606,358 series A shares and 26,359,679 series B shares, and the total number of votes will amount to 32,423,259 votes.

Commission-free sale
For the commission-free sale of redemption rights, the average sales proceeds amounted to SEK 6.41 per redemption right. Payment of proceeds of the commission-free sale of redemption rights is expected to be made to the relevant shareholders around 27 February 2015. 

Trading in redemption shares
Trading in redemption shares is expected to commence on 27 February 2015 and end on 6 March 2015.

For more information please contact:
Rein Piir, EVP Corporate Affairs & IR, mobile: +46 708 537 292.
Ola Burmark, newly appointed Chief Financial Officer Medivir AB, mobile +46 (0)725 480580.

Medivir is required under the Securities Markets Act to make the information in this press release public.
The information was submitted for publication at 9.00 CET on 27 February 2015.

About Medivir
Medivir is a research based pharmaceutical company with a research focus on infectious diseases and oncology. We have a leading competence within protease inhibitor design and nucleotide/nucleoside science and we are dedicated to develop innovative pharmaceuticals that meet great unmet medical need. Our commercial organization provides a growing portfolio of specialty care pharmaceuticals on the Nordic market.
Medivir is listed on the Nasdaq Stockholm Mid Cap List.

Tags:

About Us

Medivir is a pharmaceutical company with a focus on oncology. We have a leading competence within protease inhibitors and nucleotide/nucleoside science and we are dedicated to innovative pharmaceuticals that meet great unmet medical needs. Medivir's clinical pipeline consists of remetinostat for cutaneous T-cell lymphoma, currently in phase II, birinapant in combination with Keytruda for solid tumors, currently in phase I, MIV-818, a nucleotide prodrug drug for liver cancer that recently entered into a phase I clinical trial, and MIV-711, a potentially disease-modifying osteoarthritis candidate drug with fresh and promising data from the recent phase IIa extension study. Medivir is listed on the Nasdaq Stockholm Mid Cap List (ticker: MVIR). www.medivir.com.

Subscribe

Documents & Links